Paroxetine is an effective treatment for hot flashes: Results from a prospective randomized clinical trial

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 6919-6930

  Stearns, Vered ^a   Slack, Rebecca ^a   Greep, Nancy ^a   Henry Tilman, Ronda ^a   Osborne, Michael ^a   Bunnell, Craig ^a   Ullmer, Lynda ^a   Gallagher, Ann ^a   Cullen, Jennifer ^a   Gehan, Edmund ^a   Hayes, Daniel F ^a   Isaacs, Claudine ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; FLUOXETINE; PAROXETINE; PLACEBO; RALOXIFENE; TAMOXIFEN; VENLAFAXINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HOT FLUSH; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL FUNCTION; SLEEP DISORDER; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; BREAST TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE;

ADULT; AGED; BREAST NEOPLASMS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; PAROXETINE; PATIENT COMPLIANCE; PLACEBOS; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS;

EID: 27244436938     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.081     Document Type: Article

References (30)

1. Ganz PA, Rowland JH, Desmond K, et al: Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 16:501-514, 1998
2. Stearns V, Ullmer L, Lopez JF, et al: Hot flushes. Lancet 360:1851-1861, 2002
3. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
4. Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427, 2003
5. Holmberg L, Anderson H: HABITS (hormonal replacement therapy after breast cancer-Is it safe?), a randomised comparison: Trial stopped. Lancet 363:453-455, 2004
6. Stearns V, Isaacs C, Rowland J, et al: A pilot trial assessing the efficacy of paroxetine hydrochlonde (Paxil) in controlling hot flashes in breast cancer patients. Ann Oncol 11:17-22, 2000
7. Sloan JA, Loprinzi CL, Novotny PJ, et al: Methodologic lessons learned from hot flash studies. J Clin Oncol 19:4280-4290, 2001
8. Day R, Ganz PA, Costantino JP, et al: Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659-2669, 1999
9. Radloff LS: The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Measurement 1:385-401, 1977
10. Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361-370, 1983
11. Stewart AL, Ware JE: Measuring Functioning and Well Being: The Medical Outcomes Study Approach. Durham, NC, Duke University Press, 1992
12. Froberg DG, Kane RL: Methodology for measuring health-state preferences-I: Measurement strategies. J Clin Epidemiol 42:345-354, 1989
13. Kind P: The EuroQOL instrument: An index of health-related quality of life, in B S (ed): Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA, Lippincott-Raven, 1996
14. Loprinzi CL, Michalak JC, Quella SK, et al: Megestrol acetate for the prevention of hot flashes. N Engl J Med 331:347-352, 1994
15. Goldberg RM, Loprinzi CL, O'Fallon JR, et al: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes [erratum appears in J Clin Oncol 14:2411, 1996]. J Clin Oncol 12:155-158, 1994
16. Barton DL, Loprinzi CL, Quella SK, et al: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16:495-500, 1998
17. Senn S: Cross-Over Trials in Clinical Research. New York, NY, Wiley & Sons, 1993
18. Mehta C, Patel N: StatXact4 for Windows, led 384-388 [J-T]). Cambridge, MA, Cytel Software Corporation, 2000
19. The SAS System, (ed Proc GLM). Cary, NC, The SAS Institute, 1999
20. Scheffe H: The Analysis of Variance. New York, NY, 1959, pp 55-87
21. McNemar Q: Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12:153-157, 1947
22. Kruskal WH, Wallis WA: Use of ranks in one-criterion analysis of variance. JAMA 47:583-621, 1952
23. Piantadosi S: Clinical Trials: A Methodologic Perspective. New York, NY, Wiley & Sons, 1997
24. Loprinzi CL, Kugler JW, Sloan JA, et al: Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet 356:2059-2063, 2000
25. Loprinzi CL, Sloan JA, Perez PA, et al: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20:1578-1583, 2002
26. Stearns V, Beebe KL, Iyengar M, et al: Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. JAMA 289:2827-2834, 2003
27. Clayton AH, Pradko JF, Croft HA, et al: Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63:357-366, 2002
28. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003
29. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenomic determinants of outcome with tamoxifen therapy: Findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52. Breast Cancer Res Treat 88:314a, 2004
30. Jin Y, Desta Z, Stearns V, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005